Blueprint Medicines Backtesting

Blueprint Medicines Corporation -- USA Stock  

USD 75.13  0.2  0.27%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of Blueprint Medicines Corporation and determine expected loss or profit from investing in Blueprint Medicines over given investment horizon. Check also Blueprint Medicines Hype Analysis, Blueprint Medicines Correlation, Blueprint Medicines Valuation, Blueprint Medicines Volatility as well as analyze Blueprint Medicines Alpha and Beta and Blueprint Medicines Performance
Investment Horizon     30 Days    Login   to change

Blueprint Medicines 'What if' Analysis

November 15, 2017
No Change 0.00  0.0%
In 31 days
December 15, 2017
If you would invest  0.00  in Blueprint Medicines on November 15, 2017 and sell it all today you would earn a total of 0.00 from holding Blueprint Medicines Corporation or generate 0.0% return on investment in Blueprint Medicines over 30 days. Blueprint Medicines is related to or competes with NantKwest, Del Mar, VBI Vaccines, and Vascular Biogenics. Its lead drug candidates include BLU285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor ...

Blueprint Medicines Upside/Downside Indicators


Blueprint Medicines Market Premium Indicators

Blueprint Medicines lagged returns against current returns

 Current and Lagged Values 

Blueprint Medicines regressed lagged prices vs. current prices

 Current vs Lagged Prices 

Blueprint Medicines Backtested Returns

Macroaxis considers Blueprint Medicines not very volatile given 1 month investment horizon. Blueprint Medicines secures Sharpe Ratio (or Efficiency) of 0.141 which signifies that Blueprint Medicines had 0.141% of return per unit of risk over the last 1 month. Our philosophy towards foreseeing volatility of a stock is to use all available market data together with company specific technical indicators that cannot be diversified away. By analyzing Blueprint Medicines technical indicators you can presently evaluate if the expected return of 0.8851% is justified by implied risk. Please makes use of Blueprint Medicines Downside Deviation of 4.35, Risk Adjusted Performance of 0.0762 and Mean Deviation of 3.96 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100 Blueprint Medicines holds performance score of 9. The firm shows Beta (market volatility) of 2.8384 which signifies that as market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Blueprint Medicines will likely underperform.. Although it is vital to follow to Blueprint Medicines historical returns, it is good to be conservative about what you can actually do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. We have found twenty-one technical indicators for Blueprint Medicines Corporation which you can use to evaluate performance of the firm. Please makes use of Blueprint Medicines Treynor Ratio as well as the relationship between Potential Upside and Expected Short fall to make a quick decision on weather Blueprint Medicines price patterns will revert.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation 0.48 

Average predictability

Blueprint Medicines Corporation has average predictability. Overlapping area represents the amount of predictability between Blueprint Medicines time series from November 15, 2017 to November 30, 2017 and November 30, 2017 to December 15, 2017. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Blueprint Medicines price movement. The serial correlation of 0.48 indicates that about 48.0% of current Blueprint Medicines price fluctuation can be explain by its past prices.
Correlation Coefficient 0.48
Spearman Rank Test 0.48
Price Variance 41.16
Lagged Price Variance 9.47

Blueprint Medicines Lagged Returns

 Regressed Prices 

Blueprint Medicines Performance vs DOW

The median price of Blueprint Medicines for the period between Wed, Nov 15, 2017 and Fri, Dec 15, 2017 is 70.57 with a coefficient of variation of 8.28. The daily time series for the period is distributed with a sample standard deviation of 5.95, arithmetic mean of 71.93, and mean deviation of 4.31. The Stock received some media coverage during the period.
Price Growth (%)  
Price Target Watch on Shares of Blueprint Medicines Corporat...12/15/2017